U.S. markets open in 3 minutes
  • S&P Futures

    3,854.25
    +45.00 (+1.18%)
     
  • Dow Futures

    31,277.00
    +365.00 (+1.18%)
     
  • Nasdaq Futures

    13,080.00
    +169.00 (+1.31%)
     
  • Russell 2000 Futures

    2,240.30
    +41.10 (+1.87%)
     
  • Crude Oil

    61.57
    +0.07 (+0.11%)
     
  • Gold

    1,736.70
    +7.90 (+0.46%)
     
  • Silver

    26.96
    +0.52 (+1.97%)
     
  • EUR/USD

    1.2057
    -0.0031 (-0.25%)
     
  • 10-Yr Bond

    1.4310
    -0.0290 (-1.99%)
     
  • Vix

    24.57
    -4.32 (-14.95%)
     
  • GBP/USD

    1.3938
    +0.0016 (+0.11%)
     
  • USD/JPY

    106.6030
    +0.1010 (+0.09%)
     
  • BTC-USD

    48,041.93
    +3,301.66 (+7.38%)
     
  • CMC Crypto 200

    963.96
    +30.83 (+3.30%)
     
  • FTSE 100

    6,561.75
    +78.32 (+1.21%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
Adverum Biotechnologies, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). These data were previously presented as part of a corporate update on Saturday, November 14, 2020.

Oral Presentation Title: Intravitreal Gene Therapy for Exudative AMD and Diabetic Retinopathy
Date and Time: Saturday, February 13, 2021 at 9:30 am ET
Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy
Presenter: Arshad M. Khanani, M.D., M.A., Director of Clinical Research, Sierra Eye Associates

A copy of this presentation will be available as the presentation begins in the publications and presentation section of Adverum’s website.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

CONTACT: Investor Relations Contact Myesha Lacy Vice President, Investor Relations and Corporate Communications Adverum Biotechnologies, Inc. T: 650-649-1257 E: mlacy@adverum.com Media Contact Andrea Cohen Sam Brown Inc. T: 917-209-7163 E: andreacohen@sambrown.com